ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQRGet Rating) have earned an average recommendation of “Hold” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $5.90.

Several research firms have issued reports on PRQR. Stifel Nicolaus cut shares of ProQR Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $20.00 to $3.00 in a research note on Friday, February 11th. HC Wainwright lowered their target price on shares of ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. StockNews.com upgraded shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ProQR Therapeutics in a research report on Monday, May 9th. Finally, Chardan Capital reduced their price target on shares of ProQR Therapeutics from $8.00 to $2.50 and set a “buy” rating for the company in a research report on Thursday, April 14th.

Shares of ProQR Therapeutics stock opened at $0.69 on Tuesday. The stock has a market cap of $49.05 million, a price-to-earnings ratio of -0.64 and a beta of 0.97. The firm’s 50-day moving average is $0.80 and its 200 day moving average is $3.83. ProQR Therapeutics has a 1 year low of $0.53 and a 1 year high of $9.09. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.27 and a quick ratio of 6.94.

ProQR Therapeutics (NASDAQ:PRQRGet Rating) last posted its earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.90 million. ProQR Therapeutics had a negative net margin of 2,469.79% and a negative return on equity of 54.60%. On average, equities analysts expect that ProQR Therapeutics will post -0.86 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in PRQR. US Bancorp DE increased its holdings in ProQR Therapeutics by 122.1% in the 3rd quarter. US Bancorp DE now owns 3,693 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 2,030 shares in the last quarter. Northern Trust Corp bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $51,000. Dorsey Wright & Associates bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $55,000. ProShare Advisors LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $80,000. Finally, Monaco Asset Management SAM bought a new position in shares of ProQR Therapeutics during the 1st quarter valued at approximately $82,000.

About ProQR Therapeutics (Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.

Featured Stories

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.